论文部分内容阅读
目的探讨原发宫颈非何杰金氏淋巴瘤(NHL)的临床特点、治疗及预后。方法回顾性资料分析。结果原发宫颈NHL好发于中年。33例接触性阴道出血或不规则出血(63%);12例阴道流液或白带增多,臭味(23%);7例阴道出血和下腹不适(13%)。体征:20例宫颈糜烂(38%);13例宫颈息肉样肿物(25%);13例宫颈肿物(>3cm)(25%);10例结节样肿物(≤3cm)(19%);4例伴宫颈肥大(8%)。该肿瘤绝大多数属于B细胞型淋巴瘤(87%),其中最多为裂-无裂细胞混合型,占48%(25/52),少数为T细胞型,占13%(7/52)。按FIGO分期Ⅰ_B期40例(77.5%),Ⅱ_A期5例(10%),Ⅱ_B期4例(8%),Ⅳ期3例(6%),按Ann Arbor分期均为IE期。本组治疗是以手术为主的综合治疗。无瘤生存期2～118月,中位数大于30个月,总的5年生存率71%,其中,Ⅰ、Ⅱ、Ⅳ期分别为75%、67%、33%。结论原发宫颈非何杰金氏淋巴瘤以接触性阴道出血或不规则出血和宫颈糜烂为主要表现,病理以裂-无裂细胞混合型B细胞淋巴瘤多见。预后良好,预后与分期、病理类型、治疗方法有关。
Objective To investigate the clinical features, treatment and prognosis of primary cervical non-Hodgkin’s lymphoma (NHL). Methods Retrospective data analysis. The results of primary cervical NHL occurs in middle age. 33 cases of contact vaginal bleeding or irregular bleeding (63%); 12 cases of vaginal fluid or vaginal discharge increased, stink (23%); 7 cases of vaginal bleeding and abdominal discomfort (13%). Signs: 20 cases of cervical erosion (38%); 13 cases of cervical polyps (25%); 13 cases of cervical masses (> 3cm) (25%); 10 cases of nodular masses %); 4 cases with cervical hypertrophy (8%). Most of the tumors belonged to B-cell lymphoma (87%), most of which were mixed with cleft-non-cleaved cells (48% (25/52)) and a few were T cell types (13%, 7/52) . According to FIGO staging, 40 cases (77.5%) were in stage I_B, 5 cases (10%) in stage II_A, 4 cases (8%) in stage II_B and 3 cases (6%) in stage IV. This group of treatment is based on the comprehensive treatment of surgery. The tumor-free survival ranged from 2 to 118 months, with a median of more than 30 months and a total 5-year survival rate of 71%. Among them, stage Ⅰ, Ⅱ and Ⅳ were 75%, 67% and 33%, respectively. Conclusions Primary cervical non-Hodgkin’s lymphoma is mainly manifested by contact vaginal bleeding or irregular bleeding and cervical erosion. The pathology is more common in split-non-split cell mixed B cell lymphoma. Good prognosis, prognosis and staging, pathological types, treatment methods.